Turn Therapeutics Inc. (TTRX): Unregistered Sales of Equity Securities
Turn Therapeutics Inc. (TTRX) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. false 0002023016 0002023016 2026-08-13 2026-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15( d ) of the Securities Exchange Act of 1934 Date of Rep
How this was made
The 30-second read
Why it matters
On Aug. 13, 2026, GEM exercised the warrant in full using the cashless provision, and Turn issued 579,664 shares, reported via Item 3.02 unregistered sales of equity securities.
Market read
This is a dilution/overhang disclosure tied to a warrant cashless exercise, not a new clinical or revenue catalyst.
What to watch
Traders should check whether the cashless exercise changes future overhang (remaining warrants, potential further exercises) and whether the company simultaneously disclosed any financing or capital plan elsewhere.
Background
Turn Therapeutics previously issued a warrant to GEM Yield Bahamas Limited on Oct. 8, 2025 for 1,192,207 shares, with a cashless exercise feature tied to market value versus the $5.03 exercise price.
Ticker impact
Turn Therapeutics disclosed an unregistered warrant exercise, issuing 579,664 shares to GEM on Aug. 13, 2026 under a cashless provision.
Likely modest negative-to-neutral near term, unless the market views the warrant as already priced in.
An 8-K Item 3.02 reports the mechanics and share issuance count, which can affect dilution expectations, but it does not provide new operating or clinical fundamentals.
Market effects
Adds to the broader biotech financing overhang narrative where warrants can convert via cashless exercises.
No clear regional spillover beyond US small/mid-cap biotech sentiment.
Limited, as the disclosure is company-specific and not tied to a global macro or regulatory action.
Counterpoint
If the warrant terms were already anticipated, the incremental dilution may be largely priced in, making the filing more administrative than market-moving.
Key entities
- issuerTurn Therapeutics Inc.
Nasdaq-listed company filing the 8-K for unregistered sales of equity securities.
- counterpartyGEM Yield Bahamas Limited
Warrant holder that exercised the warrant in full on Aug. 13, 2026.
- counterpartyGEM Global Yield LLC SCS
Party to the amended and restated share purchase agreement referenced in the filing.
